Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer

  Free Subscription


Articles published in Eur Urol

Retrieve available abstracts of 176 articles:
HTML format



Single Articles


    June 2022
  1. HANEY CM, Kriegmair MC, Michel MS, Stolzenburg JU, et al
    New Evidence and Innovative Approaches to Blinding in Robot-assisted Radical Cystectomy.
    Eur Urol. 2022;81:615-617.
    PubMed    


  2. PEEKER R
    Re: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Eur Urol. 2022;81:619-620.
    PubMed    


    May 2022
  3. SOLANKI AA, Kates MR, Tran PT
    Paving the Road to the Future of Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-year Follow-up of BC2001.
    Eur Urol. 2022 May 28. pii: S0302-2838(22)02343.
    PubMed    


  4. RADZISZEWSKI P, Szablonski W
    Re: Bladder Cancer in Patients Younger than 40 Years: Outcomes from the National Cancer Database de la Calle CM, Washington SL 3rd, Lonergan PE, et al World J Urol 2021;39:1911-6.
    Eur Urol. 2022 May 19. pii: S0302-2838(22)01812.
    PubMed    


  5. HALL E, Hussain SA, Porta N, Lewis R, et al
    Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.
    Eur Urol. 2022 May 13. pii: S0302-2838(22)02265.
    PubMed     Abstract available


  6. CONROY S, Nguyen AHT
    Compound to Clinic? A Preclinical High-throughput Screening Pathway To Expedite Drug Discovery in Bladder Cancer.
    Eur Urol. 2022 May 5. pii: S0302-2838(22)01811.
    PubMed    


  7. MCGREGOR B, O'Donnell PH, Balar A, Petrylak D, et al
    Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.
    Eur Urol. 2022;81:515-522.
    PubMed     Abstract available


  8. GEAVLETE P, Multescu R, Geavlete B
    Re: How to Manage Patients with Suspected Upper Tract Urothelial Carcinoma in the Pandemic of COVID-19?
    Eur Urol. 2022;81:543.
    PubMed    


  9. SJODAHL G, Abrahamsson J, Holmsten K, Bernardo C, et al
    Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Eur Urol. 2022;81:523-532.
    PubMed     Abstract available


    April 2022
  10. LAUKHTINA E, Shariat SF
    Re: Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer.
    Eur Urol. 2022 Apr 30. pii: S0302-2838(22)01816.
    PubMed    


  11. ERTL IE, Lemberger U, Ilijazi D, Hassler MR, et al
    Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound.
    Eur Urol. 2022 Apr 4. pii: S0302-2838(22)01678.
    PubMed     Abstract available


  12. GALLIOLI A, Breda A, Palou J
    Re: Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study.
    Eur Urol. 2022;81:428-429.
    PubMed    


  13. NAKAUMA-GONZALEZ JA, Rijnders M, van Riet J, van der Heijden MS, et al
    Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
    Eur Urol. 2022;81:331-336.
    PubMed     Abstract available


    March 2022
  14. MAYR R, Eckstein M, Wirtz RM, Santiago-Walker A, et al
    Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guerin Immunotherapy.
    Eur Urol. 2022 Mar 26. pii: S0302-2838(22)01670.
    PubMed     Abstract available


  15. ALFRED WITJES J
    Re: Oncological Benefit of Re-resection for T1 Bladder Cancer: A Comparative Effectiveness Study.
    Eur Urol. 2022 Mar 25. pii: S0302-2838(22)01786.
    PubMed    


  16. WEINSTOCK C, Agrawal S, Chang E
    Optimizing Clinical Trial Design for Patients with Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2022 Mar 15. pii: S0302-2838(22)01655.
    PubMed    


  17. HENSLEY PJ, Kamat AM
    Re: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Eur Urol. 2022;81:316-317.
    PubMed    


  18. CLEMENTS MB, Atkinson TM, Dalbagni GM, Li Y, et al
    Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort.
    Eur Urol. 2022;81:294-304.
    PubMed     Abstract available


    February 2022
  19. HUNG SF, Yii SC, Chung SD
    Re: Zhiwen Chen, Peng He, Xiaozhou Zhou, et al. Preliminary Functional Outcome Following Robotic Intracorporeal Orthotopic Ileal Neobladder Suspension with Round Ligaments in Women with Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eur
    Eur Urol. 2022 Feb 9. pii: S0302-2838(22)00077.
    PubMed    


  20. PARIKH DA, Khaki AR, Williams SB
    Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study.
    Eur Urol. 2022 Feb 4. pii: S0302-2838(22)00017.
    PubMed    


  21. HE P, Zhou X, Chen Z
    Reply to Shun-Fa Hung, Shyi-Chun Yii, and Shiu-Dong Chung's Letter to the Editor re: Zhiwen Chen, Peng He, Xiaozhou Zhou, et al. Preliminary Functional Outcome Following Robotic Intracorporeal Orthotopic Ileal Neobladder Suspension with Round Ligament
    Eur Urol. 2022 Feb 3. pii: S0302-2838(22)00081.
    PubMed    


  22. RUTKA JT, Fleshner N, Nathens AB
    Re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Euro Urol 2021;80:442-9.
    Eur Urol. 2022;81:e51.
    PubMed    


    January 2022
  23. BRAUN A, Abbosh PH
    Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy: A Rare Entity with Unique Genomic Features.
    Eur Urol. 2022 Jan 30. pii: S0302-2838(22)00067.
    PubMed    


  24. BABJUK M
    Re: Long-term Experience with Radiofrequency-induced Hyperthermia Combined with Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer.
    Eur Urol. 2022 Jan 29. pii: S0302-2838(22)00023.
    PubMed    


  25. GROBET-JEANDIN E, Pinar U, Roupret M
    Re: Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study.
    Eur Urol. 2022 Jan 27. pii: S0302-2838(22)00012.
    PubMed    


  26. RENTSCH CA, Hayoz S, Cathomas RL
    Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicenter, Phase 2 Study.
    Eur Urol. 2022 Jan 24. pii: S0302-2838(22)00022.
    PubMed    


  27. SJODAHL G, Abrahamsson J, Holmsten K, Bernardo C, et al
    Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjodahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. In press. https://do
    Eur Urol. 2022 Jan 13. pii: S0302-2838(21)02284.
    PubMed    


  28. DE JONG JJ, Gibb EA
    Re: Gottfrid Sjodahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.10.035: Neoadjuvant Chemotherapy Resp
    Eur Urol. 2022 Jan 13. pii: S0302-2838(21)02281.
    PubMed    


  29. GROBET-JEANDIN E, Pinar U, Roupret M
    Re: Trey Durdin, Alvin Goh, Eugene Pietzak. Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer? Eur Urol 2021;80:16-7: Transurethral Resection of Bladder Tumor in Diagnosis of Muscle-invasive Bladder Cancer:
    Eur Urol. 2022 Jan 11. pii: S0302-2838(21)02282.
    PubMed    


  30. CARMEN MIR M, Greenwell T, O'Kelly F, Proietti S, et al
    Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur Urol 2021;80
    Eur Urol. 2022;81:e26-e27.
    PubMed    


  31. CATHOMAS R, Lorch A, Bruins HM, Comperat EM, et al
    The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma.
    Eur Urol. 2022;81:95-103.
    PubMed     Abstract available


  32. SAAD S, Osman NI, Chapple CR
    Reply to Sanjay B. Kulkarni, Pankaj M. Joshi, Marco Bandini, et al.'s Letter to the Editor re: Sanad Saad, Nadir I. Osman, Christopher R. Chapple. Female Urethra: Is Ventral the True Dorsal? Eur Urol 2020;78:e218-9.
    Eur Urol. 2022;81:e16-e17.
    PubMed    


  33. LIEDBERG F, Abrahamsson J, Bobjer J
    Re: Keisuke Shigeta, Kazuhiro Matsumoto, Koichiro Ogihara, et al. Does Neoadjuvant Chemotherapy Have Therapeutic Benefit for Node-positive Upper Tract Urothelial Carcinoma? Results of a Multi-center Cohort Study. Urol Oncol. In press. https://doi.org/
    Eur Urol. 2022;81:e18-e19.
    PubMed    


  34. SHIGETA K, Matsumoto K, Oya M
    Reply to Fredrik Liedberg, Johan Abrahamsson, and Johannes Bobjer's Letter to the Editor re: Keisuke Shigeta, Kazuhiro Matsumoto, Koichiro Ogihara, et al. Does Neoadjuvant Chemotherapy have Therapeutic Benefit for Node-positive Upper Tract Urothelial
    Eur Urol. 2022;81:e20-e21.
    PubMed    


  35. DEV S
    Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur Urol 2021;80
    Eur Urol. 2022;81:e25.
    PubMed    


    December 2021
  36. ROUMIGUIE M, Kamat AM, Bivalacqua TJ, Lerner SP, et al
    International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guerin-exposed High-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2021 Dec 23. pii: S0302-2838(21)02213.
    PubMed     Abstract available


  37. MOSSANEN M, Carvalho FLF, Muralidhar V, Preston MA, et al
    Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy.
    Eur Urol. 2021 Dec 22. pii: S0302-2838(21)02212.
    PubMed     Abstract available


  38. MITRA AP, Narayan VM, Mokkapati S, Miest T, et al
    Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.
    Eur Urol. 2021 Dec 18. pii: S0302-2838(21)02217.
    PubMed     Abstract available


    November 2021
  39. CHEN Z, He P, Zhou X, Li P, et al
    Preliminary Functional Outcome Following Robotic Intracorporeal Orthotopic Ileal Neobladder Suspension with Round Ligaments in Women with Bladder Cancer.
    Eur Urol. 2021 Nov 30. pii: S0302-2838(21)02160.
    PubMed     Abstract available


  40. REIKE MJ, Adar R, Black PC
    Not "If", but "When" and "How": Testing Antibody-Drug Conjugates in Patients with Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2021 Nov 24. pii: S0302-2838(21)02151.
    PubMed    


  41. BURDETT S, Fisher DJ, Vale CL, Bono AV, et al
    Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials.
    Eur Urol. 2021 Nov 18. pii: S0302-2838(21)02058.
    PubMed     Abstract available


  42. ROBERTSON AG, Groeneveld CS, Jordan B, Lin X, et al
    Corrigendum to "Identification of Differential Tumor Subtypes of T1 Bladder Cancer" [Eur. Urol. 78 (2020) 533-537].
    Eur Urol. 2021 Nov 17. pii: S0302-2838(21)02143.
    PubMed    


  43. PATEL SR, Lerner SP
    Re: Identification of Differential Tumor Subtypes of T1 Bladder Cancer.
    Eur Urol. 2021 Nov 16. pii: S0302-2838(21)02119.
    PubMed    


  44. MIRON B, Bukavina L, Plimack ER
    Placing Adjuvant Chemotherapy in the Evolving Paradigm of Perioperative Therapy for Bladder Cancer.
    Eur Urol. 2021 Nov 5. pii: S0302-2838(21)02121.
    PubMed    


  45. CHOI W, Lombardo K, Patel S, Epstein G, et al
    A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guerin-exposed Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2021 Nov 1. pii: S0302-2838(21)02077.
    PubMed     Abstract available


    October 2021
  46. WOLDU SL, Lotan Y
    Re: ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma.
    Eur Urol. 2021;80:517-518.
    PubMed    


  47. TEOH JY, Murphy DG, van Oort IM, Loeb S, et al
    Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9.
    Eur Urol. 2021;80:e101.
    PubMed    


  48. FOERSTER B, Abufaraj M, Matin SF, Azizi M, et al
    Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study.
    Eur Urol. 2021;80:507-515.
    PubMed     Abstract available


    September 2021
  49. BABJUK M, Burger M, Capoun O, Cohen D, et al
    European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
    Eur Urol. 2021 Sep 9. pii: S0302-2838(21)01978.
    PubMed     Abstract available


  50. CLINTON TN
    Defining Resistance to Immune Checkpoint Inhibitors in Urothelial Carcinoma: Insights from PURE-01.
    Eur Urol. 2021;80:323-324.
    PubMed    


    August 2021
  51. KARTOLO A, Kassouf W, Vera-Badillo FE
    Adjuvant Immune Checkpoint Inhibition in Muscle-invasive Bladder Cancer: Is It Ready for Prime Time?
    Eur Urol. 2021 Aug 5. pii: S0302-2838(21)01922.
    PubMed     Abstract available


  52. LI R, Jain RK, Sexton WJ
    Re: Andrea Necchi, Laura Marandino, Daniele Raggi, et al. Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? Eur Urol 2021;79:713-6.
    Eur Urol. 2021 Aug 4. pii: S0302-2838(21)01925.
    PubMed    


  53. KESAVAN A, Esuvaranathan K
    Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study.
    Eur Urol. 2021 Aug 4. pii: S0302-2838(21)01923.
    PubMed    


  54. BEDKE J, Maas M
    Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
    Eur Urol. 2021;80:257-258.
    PubMed    


  55. MASSON-LECOMTE A, Meria P
    Re: Complications Associated with Ureteroscopic Management of Upper Tract Urothelial Carcinoma.
    Eur Urol. 2021;80:255.
    PubMed    


  56. SATISH P, Kuusk T, Campain N, Abu-Ghanem Y, et al
    The European Association of Urology COVID Intermediate-priority Group is Poorly Predictive of Pathological High Risk Among Patients with Renal Tumours.
    Eur Urol. 2021;80:265-267.
    PubMed    


  57. DELL'OGLIO P, Andras I, Ortega D, Galfano A, et al
    Impact of the Implementation of the EAU Guidelines Recommendation on Reporting and Grading of Complications in Patients Undergoing Robot-assisted Radical Cystectomy: A Systematic Review.
    Eur Urol. 2021;80:129-133.
    PubMed     Abstract available


    July 2021
  58. ALFRED WITJES J
    Re: Five-factor Prognostic Model for Survival of Post-platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
    Eur Urol. 2021;80:113.
    PubMed    


  59. VAN DER HEIJDEN MS, Loriot Y, Duran I, Ravaud A, et al
    Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.
    Eur Urol. 2021;80:7-11.
    PubMed     Abstract available


  60. LI R, Gilbert SM, Kamat AM
    Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-Guerin.
    Eur Urol. 2021;80:1-3.
    PubMed     Abstract available


    June 2021
  61. HU H
    Re: Richard T. Bryan, Wenyu Liu, Sarah J. Pirrie, et al. Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study. Eur Urol 2021;80:12-5.
    Eur Urol. 2021 Jun 29. pii: S0302-2838(21)01859.
    PubMed    


  62. KULKARNI GS
    Re: Radical Cystectomy Against Intravesical BCG for High-risk High-grade Nonmuscle Invasive Bladder Cancer: Results from the Randomized Controlled BRAVO-feasibility Study.
    Eur Urol. 2021 Jun 23. pii: S0302-2838(21)01803.
    PubMed    


  63. CIMADAMORE A, Lopez-Beltran A, Scarpelli M, Montironi R, et al
    Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489-91.
    Eur Urol. 2021;79:e172-e173.
    PubMed    


  64. JONES TD, Cheng L
    Reply to Alessia Cimadamore, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Sys
    Eur Urol. 2021;79:e174-e175.
    PubMed    


    May 2021
  65. PEDERZOLI F, Bandini M, Raggi D, Marandino L, et al
    Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00387.
    PubMed     Abstract available


  66. HUSSAIN SA, Porta N, Hall E, Qureshi M, et al
    Reply to Santhanam Sundar and Paul Symonds' Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00347.
    PubMed    


  67. SUNDAR S, Symonds P
    Re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. Eur Urol 2021;79:307-15.
    Eur Urol. 2021 May 20. pii: S0302-2838(21)00345.
    PubMed    


  68. BRYAN RT, Catto JWF, Jefferson KP, Patel P, et al
    Reply to Trey Durdin, Alvin Goh, and Eugene Pietzak. Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.018.
    Eur Urol. 2021 May 7. pii: S0302-2838(21)00313.
    PubMed    


  69. PATEL SH, Kates M
    Open Versus Robot-assisted Radical Cystectomy: Is Standardization Without Randomization Possible?
    Eur Urol. 2021;79:619-620.
    PubMed    


  70. GAKIS G
    Re: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
    Eur Urol. 2021;79:702.
    PubMed    


  71. LEOW JJ, Chong YL, Chang SL, Valderrama BP, et al
    Reply to Alexander Andreev-Drakhlin, Jianjun Gao, Arlene Siefker-Radtke. Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma. Eur Urol 2021;79:655-6.
    Eur Urol. 2021;79:657-658.
    PubMed    


  72. ANDREEV-DRAKHLIN A, Gao J, Siefker-Radtke A
    Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma.
    Eur Urol. 2021;79:655-656.
    PubMed    


  73. LEOW JJ, Chong YL, Chang SL, Valderrama BP, et al
    Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy.
    Eur Urol. 2021;79:635-654.
    PubMed     Abstract available


    April 2021
  74. DURDIN T, Goh A, Pietzak E
    Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer?
    Eur Urol. 2021 Apr 8. pii: S0302-2838(21)00224.
    PubMed    


  75. ROUMIGUIE M, Contreras-Sanz A, Black PC
    Re: Ming Yuen Teo, Jose Mauricio Mota, Karissa A. Whiting, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
    Eur Urol. 2021 Apr 7. pii: S0302-2838(21)00234.
    PubMed    


  76. PIAZZA P, Rosiello G, Chacon VT, Puliatti S, et al
    Robot-assisted Cystectomy with Intracorporeal Urinary Diversion After Pelvic Irradiation for Prostate Cancer: Technique and Results from a Single High-volume Center.
    Eur Urol. 2021 Apr 7. pii: S0302-2838(21)00229.
    PubMed     Abstract available


  77. JONES TD, Cheng L
    Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups.
    Eur Urol. 2021;79:489-491.
    PubMed    


  78. FUKUOKAYA W, Egawa S
    Re: Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.
    Eur Urol. 2021;79:553-554.
    PubMed    


  79. XU P, Chen B, Xu A, Yuan D, et al
    Initial Experience with Intracorporeal Laparoscopic Radical Cystectomy and Detaenial Sigmoid Neobladder Reconstruction.
    Eur Urol. 2021;79:545-551.
    PubMed     Abstract available


    March 2021
  80. NECCHI A, de Jong JJ, Raggi D, Briganti A, et al
    Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.
    Eur Urol. 2021 Mar 27. pii: S0302-2838(21)00212.
    PubMed     Abstract available


  81. GRIMM MO, Leucht K
    Re: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
    Eur Urol. 2021;79:429-430.
    PubMed    


    February 2021
  82. BRYAN RT, Liu W, Pirrie SJ, Amir R, et al
    Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study.
    Eur Urol. 2021 Feb 27. pii: S0302-2838(21)00141.
    PubMed     Abstract available


  83. ROSIELLO G, Piazza P, Tames V, Farinha R, et al
    The Impact of Previous Prostate Surgery on Surgical Outcomes for Patients Treated with Robot-assisted Radical Cystectomy for Bladder Cancer.
    Eur Urol. 2021 Feb 27. pii: S0302-2838(21)00149.
    PubMed     Abstract available


  84. ABU-SALHA Y, Smith AB
    Seeing the Unseen: Uncovering Patient-reported Outcomes in Bladder Cancer.
    Eur Urol. 2021 Feb 23. pii: S0302-2838(21)00143.
    PubMed    


  85. GRABBERT M, Seiler R, Gratzke C
    Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial Boorjian SA, Alemozaffar M, Konety BR, et al Lancet Oncol 2021;22:107-17.
    Eur Urol. 2021 Feb 20. pii: S0302-2838(21)00099.
    PubMed    


  86. SIGNORINI C, Maffezzini M
    Re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomized Controlled Trial. Eur Urol 2020;78:
    Eur Urol. 2021 Feb 13. pii: S0302-2838(21)00075.
    PubMed    


  87. LINDGREN MS, Jensen JB
    Reply to Claudia Signorini and Massimo Maffezzini's Letter to the Editor re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle
    Eur Urol. 2021 Feb 13. pii: S0302-2838(21)00085.
    PubMed    


  88. CATTO JWF, Downing A, Mason S, Wright P, et al
    Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes.
    Eur Urol. 2021 Feb 10. pii: S0302-2838(21)00073.
    PubMed     Abstract available


  89. SORIA F, Gontero P
    Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial.
    Eur Urol. 2021 Feb 4. pii: S0302-2838(21)00066.
    PubMed    


  90. ALFRED WITJES J
    Re: Optimal Cystectomy Outcome: A Composite Measurement Evaluating Quality of Care and Mortality Benefit.
    Eur Urol. 2021;79:316.
    PubMed    


    January 2021
  91. LI R, Lerner SP, Kamat AM
    The Who, What, When, Where, and Why of Bacillus Calmette-Guerin-unresponsive Bladder Cancer.
    Eur Urol. 2021 Jan 13. pii: S0302-2838(21)00001.
    PubMed     Abstract available


  92. WIJBURG CJ, Michels CTJ, Grutters JPC, Rovers MM, et al
    Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Bladder Cancer Patients: A Multicentre Comparative Effectiveness Study.
    Eur Urol. 2021 Jan 11. pii: S0302-2838(20)31009.
    PubMed     Abstract available


  93. SYLVESTER RJ, Rodriguez O, Hernandez V, Turturica D, et al
    European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.
    Eur Urol. 2021 Jan 5. pii: S0302-2838(20)31019.
    PubMed     Abstract available


  94. PERERA-BEL J, Bellmunt J
    Reply to Anirban P. Mitra, Tanner Miest, and Colin P.N. Dinney's Words of Wisdom re: Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.euru
    Eur Urol. 2021 Jan 5. pii: S0302-2838(20)31024.
    PubMed    


  95. FODE M, Jensen CFS, Ostergren PB
    How Should the Medical Community Respond to the Low Quality of Medical Information on Social Media?
    Eur Urol. 2021;79:60-61.
    PubMed    


    December 2020
  96. GIANNARINI G, Valotto C, Ficarra V
    Re: Health Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial: A Multi-institutional Randomized Trial Comparing Robot Versus Open Radical Cystectomy.
    Eur Urol. 2020 Dec 19. pii: S0302-2838(20)30954.
    PubMed    


  97. POLETAJEW S, Krajewski W, Zdrojowy R, Kryst P, et al
    Re: Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
    Eur Urol. 2020 Dec 10. pii: S0302-2838(20)30928.
    PubMed    


  98. HUSSAIN SA, Porta N, Hall E, Salawu A, et al
    Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial.
    Eur Urol. 2020 Dec 5. pii: S0302-2838(20)30937.
    PubMed     Abstract available


  99. DE VERE WHITE R, Dall'Era M
    Re: Quality Indicators for Bladder Cancer Services: A Collaborative Review.
    Eur Urol. 2020 Dec 5. pii: S0302-2838(20)30932.
    PubMed    


  100. MANTICA G, Terrone C, Der Merwe AV
    Bladder Cancer and Associated Risk Factors: The African Panorama.
    Eur Urol. 2020 Dec 3. pii: S0302-2838(20)30942.
    PubMed     Abstract available


    November 2020
  101. PANEBIANCO V, Del Giudice F, Narumi Y, Simone G, et al
    Re: Helena Vila-Reyes, G. Joel DeCastro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imag
    Eur Urol. 2020 Nov 28. pii: S0302-2838(20)30861.
    PubMed    


  102. VILA-REYES H, Joel DeCastro G, McKiernan JM
    Reply to Valeria Panebianco, Francesco Del Giudice, Yoshifumi Narumi, Giuseppe Simone, Ettore De Berardinis, and James Catto's Letter to the Editor re: Helena Vila-Reyes, G. Joel De Castro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai,
    Eur Urol. 2020 Nov 25. pii: S0302-2838(20)30883.
    PubMed    


  103. IYER G, Bochner BH, Van Allen EM, Solit DB, et al
    Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eu
    Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30865.
    PubMed    


  104. BECKER REN, Baras A, Bivalacqua TJ
    Reply to Gopa Iyer, Bernard H. Bochner, Eliezer M. Van Allen, David B. Solit, and Jonathan E. Rosenberg's Letter to the Editor re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicato
    Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30864.
    PubMed    


  105. BAKER SC, Mason AS, Southgate J
    Does a Novel Mutagenic Process Target KMT2D Mutation in the Most Common First Event on the Path to Bladder Cancer?
    Eur Urol. 2020 Nov 14. pii: S0302-2838(20)30866.
    PubMed    


  106. MITRA AP, Miest T, Dinney CPN
    Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer.
    Eur Urol. 2020 Nov 3. pii: S0302-2838(20)30809.
    PubMed    


    October 2020
  107. RIAZ IB, Hussain SA
    Perioperative Treatment in Muscle-invasive Bladder Cancer: Analysis of Secondary Endpoints in a Randomized Trial Comparing Gemcitabine and Cisplatin Versus Dose-dense Methotrexate, Vinblastine, Adriamycin, and Cisplatin.
    Eur Urol. 2020 Oct 1. pii: S0302-2838(20)30710.
    PubMed    


  108. SHAH A, Tan WP, Inman BA
    National Quality Improvement Program in Transurethral Resection of Bladder Tumor: A Model for the Rest of Us, Even if We Cannot Share All Results.
    Eur Urol. 2020;78:531-532.
    PubMed    


  109. GRIMBERG DC, Shah A, Inman BA
    En Bloc Resection of Bladder Tumors: Style or Substance?
    Eur Urol. 2020;78:570-571.
    PubMed    


    September 2020
  110. LOEB S, Reines K, Abu-Salha Y, French W, et al
    Quality of Bladder Cancer Information on YouTube.
    Eur Urol. 2020 Sep 30. pii: S0302-2838(20)30706.
    PubMed     Abstract available


  111. LIEDBERG F, Eriksson P, Sjodahl G
    Re: A. Gordon Robertson, Clarice S. Groeneveld, Brian Jordan, et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol. In press. http://doi.org/10.1016/j.eururo.2020.06.048.
    Eur Urol. 2020 Sep 28. pii: S0302-2838(20)30708.
    PubMed    


  112. MEEKS JJ, Dyrsjkot L, Robertson AG
    Reply to Fredrik Liedberg, Pontus Eriksson, and Gottfrid Sjodahl's Letter to the Editor re: A. Gordon Robertson, Clarice S. Groeneveld, Brian Jordan, et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol. In press. http:/
    Eur Urol. 2020 Sep 26. pii: S0302-2838(20)30722.
    PubMed    


  113. PACKIAM VT, Bhindi B
    Are We Moving Closer to Accurate Restaging after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer?
    Eur Urol. 2020 Sep 23. pii: S0302-2838(20)30711.
    PubMed    


  114. TEOH JY, Huang J, Ko WY, Lok V, et al
    Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita.
    Eur Urol. 2020 Sep 21. pii: S0302-2838(20)30697.
    PubMed     Abstract available


    August 2020
  115. PANER GP, Montironi R
    Re: J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.03
    Eur Urol. 2020 Aug 29. pii: S0302-2838(20)30631.
    PubMed    


  116. PFISTER C, Gravis G, Flechon A, Soulie M, et al
    Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Sec
    Eur Urol. 2020 Aug 28. pii: S0302-2838(20)30641.
    PubMed     Abstract available


  117. NECCHI A, Marandino L, Raggi D, Bandini M, et al
    Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer?
    Eur Urol. 2020 Aug 27. pii: S0302-2838(20)30639.
    PubMed     Abstract available


  118. FLIPPOT R, Loriot Y
    The FGFR3 Story in Bladder Cancer: Another Piece of the Puzzle?
    Eur Urol. 2020 Aug 24. pii: S0302-2838(20)30633.
    PubMed    


  119. VILA-REYES H, DeCastro GJ, McKiernan JM
    Re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscl
    Eur Urol. 2020 Aug 20. pii: S0302-2838(20)30623.
    PubMed    


  120. BALDAUF A, Koch R, Heberling U, Thomas C, et al
    Re: J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.03
    Eur Urol. 2020 Aug 17. pii: S0302-2838(20)30617.
    PubMed    


  121. BECKER REN, Meyer AR, Brant A, Reese AC, et al
    Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
    Eur Urol. 2020 Aug 17. pii: S0302-2838(20)30564.
    PubMed     Abstract available


  122. MOSTAFID H
    Neoadjuvant Intravesical Therapy for Non-muscle-invasive Bladder Cancer: A New Approach for Old Agents?
    Eur Urol. 2020 Aug 9. pii: S0302-2838(20)30598.
    PubMed    


  123. WARD DG, Arnold R, Bryan RT
    Molecular Subtypes of T1 Bladder Cancer: Biomolecular Characteristics Versus Clinical Utility.
    Eur Urol. 2020 Aug 6. pii: S0302-2838(20)30569.
    PubMed    


  124. MONTORSI F, Bandini M, Necchi A
    Re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive
    Eur Urol. 2020;78:e75-e76.
    PubMed    


    July 2020
  125. MONTORSI F, Bandini M, Briganti A, Dasgupta P, et al
    Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations.
    Eur Urol. 2020 Jul 28. pii: S0302-2838(20)30464.
    PubMed     Abstract available


  126. LINDGREN MS, Bue P, Azawi N, Blichert-Refsgaard L, et al
    The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial.
    Eur Urol. 2020 Jul 28. pii: S0302-2838(20)30541.
    PubMed     Abstract available


  127. WITJES JA, Ribal MJ, van der Heijden AG
    Reply to Francesco Montorsi, Marco Bandini, Alberto Briganti, et al. Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations. Eur Urol. In press: Ca
    Eur Urol. 2020 Jul 18. pii: S0302-2838(20)30538.
    PubMed    


  128. MARIAPPAN P, Johnston A, Padovani L, Clark E, et al
    Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
    Eur Urol. 2020 Jul 17. pii: S0302-2838(20)30511.
    PubMed     Abstract available


  129. ROBERTSON AG, Groeneveld CS, Jordan B, Lin X, et al
    Identification of Differential Tumor Subtypes of T1 Bladder Cancer.
    Eur Urol. 2020 Jul 16. pii: S0302-2838(20)30508.
    PubMed     Abstract available


  130. VAN RHIJN BWG, Mertens LS, Mayr R, Bostrom PJ, et al
    FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?(dagger).
    Eur Urol. 2020 Jul 15. pii: S0302-2838(20)30531.
    PubMed     Abstract available


  131. COMPERAT E
    Re: Greater Utility of Molecular Subtype Rather than Epithelial-to-mesenchymal Transition (EMT) Markers for Prognosis in High-risk Non-muscle-invasive (HGT1) Bladder Cancer.
    Eur Urol. 2020 Jul 3. pii: S0302-2838(20)30448.
    PubMed    


  132. WATERHOUSE JV, Hull JH, Linch M
    Corticosteroids for Urological Cancer Care During Coronavirus Disease 2019. Treat or Not to Treat?
    Eur Urol. 2020;78:9-10.
    PubMed     Abstract available


    June 2020
  133. MEEKS JJ, Robertson AG
    Immune Signatures Dominate Molecular Subtyping to Predict Response to Neoadjuvant Immunotherapy.
    Eur Urol. 2020;77:711-712.
    PubMed    


    May 2020
  134. WITJES JA, Babjuk M, Bellmunt J, Bruins HM, et al
    Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250
    Eur Urol. 2020 May 20. pii: S0302-2838(20)30192.
    PubMed    


  135. MARIAPPAN P
    Propensity for Quality: No Longer a Tenuous Proposition in Bladder Cancer.
    Eur Urol. 2020 May 19. pii: S0302-2838(20)30218.
    PubMed    


  136. VETTERLEIN MW, Gild P, Fisch M, Rink M, et al
    Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of U
    Eur Urol. 2020 May 3. pii: S0302-2838(20)30314.
    PubMed    


  137. BABJUK M
    Re: Multi-institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
    Eur Urol. 2020 May 3. pii: S0302-2838(20)30252.
    PubMed    


  138. BABJUK M
    Are the Role of Surgery and its Complications Sufficiently Focused in the Era of Perioperative Systemic Treatments?
    Eur Urol. 2020;77:581-582.
    PubMed    


  139. MANTICA G, Terrone C
    Re: Eugene Shkolyar, Xiao Jia, Timothy C. Chang, et al. Augmented Bladder Tumor Detection Using Deep Learning. Eur Urol 2019;76:714-8.
    Eur Urol. 2020;77:e133.
    PubMed    


    April 2020
  140. WITJES JA, Bruins HM, Cathomas R, Comperat EM, et al
    European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.
    Eur Urol. 2020 Apr 29. pii: S0302-2838(20)30230.
    PubMed     Abstract available


  141. WOERL AC, Eckstein M, Geiger J, Wagner DC, et al
    Deep Learning Predicts Molecular Subtype of Muscle-invasive Bladder Cancer from Conventional Histopathological Slides.
    Eur Urol. 2020 Apr 27. pii: S0302-2838(20)30255.
    PubMed     Abstract available


  142. KAMAT AM
    Bladder Cancer Guidelines: Let Not the Cure Be Worse than the Disease.
    Eur Urol. 2020 Apr 27. pii: S0302-2838(20)30322.
    PubMed    


  143. PANEBIANCO V, Del Giudice F, Leonardo C, Sciarra A, et al
    VI-RADS Scoring Criteria for Alternative Risk-adapted Strategies in the Management of Bladder Cancer During the COVID-19 Pandemic.
    Eur Urol. 2020 Apr 27. pii: S0302-2838(20)30306.
    PubMed    


  144. LOUIS L, Thomas S, Yohann L, Morgan R, et al
    Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Guerin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic.
    Eur Urol. 2020 Apr 24. pii: S0302-2838(20)30302.
    PubMed     Abstract available


  145. SHAH A, Grimberg DC, Inman BA
    From Dog's Breakfast to Michelin Guide: Post-bacillus Calmette-Guerin Trials in Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2020 Apr 14. pii: S0302-2838(20)30197.
    PubMed    


    March 2020
  146. BAI Y, Yang Y, Tang Y
    Re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-0
    Eur Urol. 2020 Mar 18. pii: S0302-2838(20)30149.
    PubMed    


  147. NECCHI A, Gallina A, Dyrskjot L, Roupret M, et al
    Converging Roads to Early Bladder Cancer.
    Eur Urol. 2020 Mar 17. pii: S0302-2838(20)30141.
    PubMed    


  148. MOSTAFID H, Babjuk M, Bochner B, Lerner SP, et al
    Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer.
    Eur Urol. 2020 Mar 16. pii: S0302-2838(20)30146.
    PubMed     Abstract available


  149. BANDINI M, Necchi A
    Reply to Yunjin Bai, Yubo Yang, Yin Tang's Letter to the Editor, re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Mus
    Eur Urol. 2020 Mar 14. pii: S0302-2838(20)30150.
    PubMed    


  150. HUDDART R, Hall E, Lewis R, Porta N, et al
    Reply to Wei Liu, Xiaoping Liu, Sheng Li's Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy +/- Chemotherap
    Eur Urol. 2020 Mar 10. pii: S0302-2838(20)30119.
    PubMed    


  151. NECCHI A, Raggi D, Gallina A, Ross JS, et al
    Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
    Eur Urol. 2020 Mar 9. pii: S0302-2838(20)30138.
    PubMed     Abstract available


  152. LI R, Sundi D, Zhang J, Kim Y, et al
    Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guerin.
    Eur Urol. 2020 Mar 3. pii: S0302-2838(20)30118.
    PubMed     Abstract available


    February 2020
  153. LIU W, Liu X, Li S
    Re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy +/- Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol.
    Eur Urol. 2020 Feb 26. pii: S0302-2838(20)30120.
    PubMed    


  154. KAMOUN A, de Reynies A, Allory Y, Sjodahl G, et al
    Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol. In press.
    Eur Urol. 2020 Feb 6. pii: S0302-2838(19)30958.
    PubMed    


    January 2020
  155. DEL GIUDICE F, Catto JWF, Panebianco V
    Reply to Charalampos Fragkoulis, Georgios Papadopoulos, and Konstantinos Ntoumas's Letter to the Editor re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI
    Eur Urol. 2020 Jan 28. pii: S0302-2838(20)30056.
    PubMed    


  156. FRAGKOULIS C, Papadopoulos G, Ntoumas K
    Re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patient
    Eur Urol. 2020 Jan 21. pii: S0302-2838(20)30053.
    PubMed    


  157. BRIGANTI A, Gandaglia G, Scuderi S, Gallina A, et al
    Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial.
    Eur Urol. 2020 Jan 3. pii: S0302-2838(19)30963.
    PubMed     Abstract available


  158. MCGRATH JS, Smith AB, Williams SB
    The Complexity of Complications: How Do We Estimate Morbidity and Target Improvements Following Radical Cystectomy?
    Eur Urol. 2020;77:66-67.
    PubMed    


  159. VETTERLEIN MW, Rink M
    Reply to Liang Sun and Yi Feng's Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Sta
    Eur Urol. 2020;77:e12-e13.
    PubMed    


  160. SUN L, Feng Y
    Re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive
    Eur Urol. 2020;77:e10-e11.
    PubMed    


  161. KHAN MS, Omar K, Ahmed K, Gan C, et al
    Long-term Oncological Outcomes from an Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).
    Eur Urol. 2020;77:110-118.
    PubMed     Abstract available


  162. MOSCHINI M, Shariat SF, Black P, Kamat AM, et al
    Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails.
    Eur Urol. 2020;77:1-2.
    PubMed     Abstract available


  163. VETTERLEIN MW, Klemm J, Gild P, Bradtke M, et al
    Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index.
    Eur Urol. 2020;77:55-65.
    PubMed     Abstract available


    December 2019
  164. NECCHI A, Bandini M, Calareso G, Raggi D, et al
    Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study.
    Eur Urol. 2019 Dec 24. pii: S0302-2838(19)30960.
    PubMed     Abstract available


  165. HUDDART RA, Hall E, Lewis R, Porta N, et al
    Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy +/- Chemotherapy in the BC2001 Phase III Randomised Controlled Trial.
    Eur Urol. 2019 Dec 13. pii: S0302-2838(19)30840.
    PubMed     Abstract available


  166. THIBAULT C, Lavaud P, Loriot Y
    Studying Rarity in Bladder Cancer.
    Eur Urol. 2019 Dec 4. pii: S0302-2838(19)30891.
    PubMed    


    November 2019
  167. WILLIAMS SB, Black PC, Dyrskjot L, Seiler R, et al
    Re: Aurelie Kamoun, Aurelien de Reynies, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.09.006: A Statement from the International Bladder Cancer Ne
    Eur Urol. 2019 Nov 28. pii: S0302-2838(19)30874.
    PubMed    


  168. WITJES JA, Babjuk M, Bellmunt J, Bruins HM, et al
    EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort(dagger): Under the Auspices of the EAU-ESMO Guidelines Committees.
    Eur Urol. 2019 Nov 16. pii: S0302-2838(19)30763.
    PubMed     Abstract available


  169. DEL GIUDICE F, Barchetti G, De Berardinis E, Pecoraro M, et al
    Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
    Eur Urol. 2019 Nov 4. pii: S0302-2838(19)30757.
    PubMed     Abstract available


    October 2019
  170. YATAI KB, Tran H, Dunning MJ, Wang D, et al
    Sources of Bias Within Consensus Subtypes of Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Oct 23. pii: S0302-2838(19)30760.
    PubMed    


    September 2019
  171. KETTUNEN K, Bostrom P, Taimen P
    Reply to Xuefeng Liu's Letter to the Editor, re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In press. https://do
    Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30731.
    PubMed    


  172. LIU X
    Re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.06.016: Can Patie
    Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30734.
    PubMed    


  173. KRIEGMAIR MC, Rother J, Grychtol B, Theuring M, et al
    Multiparametric Cystoscopy for Detection of Bladder Cancer Using Real-time Multispectral Imaging.
    Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30674.
    PubMed     Abstract available


  174. KAMOUN A, Reynies A, Allory Y, Sjodahl G, et al
    A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Sep 25. pii: S0302-2838(19)30695.
    PubMed     Abstract available


  175. LEOW JJ, Catto JWF, Efstathiou JA, Gore JL, et al
    Quality Indicators for Bladder Cancer Services: A Collaborative Review.
    Eur Urol. 2019 Sep 25. pii: S0302-2838(19)30690.
    PubMed     Abstract available


    May 2019
  176. SUNDAHL N, Vandekerkhove G, Decaestecker K, Meireson A, et al
    Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma.
    Eur Urol. 2019;75:707-711.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: